Today: 10 June 2026
Browse Category

NYSE:NVO 8 November 2025 - 14 December 2025

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk shares rebounded this week, rising about 7% in both Copenhagen and U.S. trading after EU regulators backed a higher-dose Wegovy, Ozempic launched in India at a lower price, and the company closed its Akero Therapeutics acquisition. The week began with a sharp selloff on competition fears and a Wall Street downgrade before sentiment reversed midweek.
14 December 2025
····
Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk shares have dropped about 45% in 2025 and over 50% from their 2024 peak, following profit warnings, slower GLP-1 growth, and a failed Alzheimer’s trial. The stock now trades near $47.9, down sharply after the EVOKE and EVOKE+ studies showed no significant benefit for semaglutide in early Alzheimer’s. Revenue in Q3 2025 rose 5% to DKK 74.98 billion, missing analyst expectations.
7 December 2025
··
Novo Nordisk Stock Today, 28 November 2025: Goldman Sachs Trims Target as Obesity Pipeline Fights Back

Novo Nordisk Stock Today, 28 November 2025: Goldman Sachs Trims Target as Obesity Pipeline Fights Back

Novo Nordisk ADRs traded near $49.25 Friday, up about 1%, with volume topping 6.7 million shares. Goldman Sachs cut its 12-month price target to $54 from $60 but kept a “Buy” rating, implying about 10% upside. Novo’s Copenhagen shares remain down nearly 49% year to date. Analyst targets have drifted lower, with consensus now around $54–57 per ADR.
28 November 2025
·
Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk shares rebounded sharply on 26 November, with U.S. ADRs up 3.7% to $48.79 and Copenhagen shares closing 4.7% higher at DKK 314.20. The rally followed an FDA filing for a higher-dose Wegovy, Medicare pricing clarity, and renewed interest in the company’s next-generation obesity drug. Despite the gains, Copenhagen shares remain down nearly 50% year-to-date.
26 November 2025
···
NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

Novo Nordisk ADRs rose 4.7% to $47.08 in late trading Tuesday after mid-stage trial data showed its experimental obesity drug amycretin led to up to 14.5% weight loss in type 2 diabetes patients. The rebound follows a 5% drop Monday on failed Alzheimer’s trials. NVO remains down over 50% in the past year and trades near 52-week lows amid guidance cuts and competition from Eli Lilly.
25 November 2025
··
US Stock Market Today, Nov. 24, 2025: Futures Rise on Fed Rate-Cut Hopes, Bitcoin Rebound and Novo Nordisk Shock Before the Opening Bell

US Stock Market Today, Nov. 24, 2025: Futures Rise on Fed Rate-Cut Hopes, Bitcoin Rebound and Novo Nordisk Shock Before the Opening Bell

U.S. stock futures rose Monday, with Dow, S&P 500, and Nasdaq up 0.3% to 1% pre-market as traders bet on a possible December Fed rate cut. Bitcoin rebounded above $85,000, boosting crypto stocks. Novo Nordisk shares fell sharply after its Alzheimer’s trial failed. No major U.S. economic data is due today due to a government shutdown delay.
25 November 2025
···
BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

Biogen shares hit a 52-week high Monday, closing at $177.42, up 1.2%, after Novo Nordisk’s Alzheimer’s drug failed in late-stage trials. The stock traded as high as $185.17 intraday on volume of about 2.07 million shares. Investors also reacted to Biogen’s new immunology partnership with Dayra Therapeutics. Novo shares fell sharply on the trial news.
24 November 2025
··
Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk’s U.S. shares fell 1.1% to $47.07 by late morning, while Copenhagen B-shares closed down nearly 3% at DKK 305, extending a year-to-date drop of about 45%. Denmark compensated four patients for vision loss linked to Wegovy and Ozempic. Novo Nordisk and Eli Lilly launched direct-to-employer GLP-1 drug programs, and Novo cut self-pay prices for its weight-loss drugs.
21 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk’s U.S. ADR traded near $49 Thursday, steady after a 3% rebound, while Copenhagen shares rose about 2–2.5% to DKK 318–319. The company faces slowing GLP-1 demand, price cuts, and high-profile Alzheimer’s trials, with results expected December 3. Shares remain down over 10% in three months and nearly 46% year-to-date after guidance cuts.
20 November 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Novo Nordisk cut U.S. self-pay prices for Wegovy and Ozempic and launched a $199 two-month introductory offer for new patients. Shares fell 1.9% to $47.55 intraday as investors weighed pricing pressure and governance changes. Novo Holdings exited its 7.8% stake in ConvaTec in London. Trading volumes reached about 7.9 million shares by 16:12 UTC.
18 November 2025
··
LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD announced $199 monthly cash-pay pricing for starter doses of Wegovy and Ozempic, available to new patients for their first two fills through its Weight Management Program. The move follows a partnership with Novo Nordisk and comes hours before LifeMD’s delayed Q3 2025 earnings release, rescheduled for Nov. 17. LFMD shares traded around $4.60 this afternoon, slightly down despite the news.
17 November 2025
··
Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio shares plunged nearly 80% to around $6.60 in pre-market trading Thursday after the company reported mixed early data from its lead RNA-editing program, KRRO‑110, and announced layoffs, a pipeline shift, and a year-long pause in its Novo Nordisk partnership. The Phase 1/2a trial showed KRRO‑110 increased AAT protein but did not reach protective levels.
13 November 2025
··
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

WeightWatchers plans to offer Novo Nordisk’s oral Wegovy in the U.S. after its expected 2026 launch. Sandoz says unbranded Ozempic could reach Canada by June 2026, intensifying price competition. CVS dropped Lilly’s Zepbound from its preferred list, keeping Wegovy, prompting Lilly to move employees off CVS plans. Novo Nordisk shares traded at $49.76 late Wednesday, up slightly.
12 November 2025
·····
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera shares fell about 15% Monday after the company accepted Pfizer’s revised takeover offer, ending a bidding war with Novo Nordisk. Pfizer will pay $65.60 per share in cash plus up to $20.65 in contingent value rights. Novo withdrew its bid over the weekend. Metsera cited U.S. FTC antitrust concerns with Novo’s proposal.
10 November 2025
····
Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

U.S. stock futures rose Monday as Senate action fueled hopes for an end to the government shutdown, with Nvidia up 3% premarket. Pfizer won the $10 billion Metsera bid, sending Novo Nordisk shares higher in Copenhagen. Rumble agreed to buy Germany’s Northern Data in an all-stock deal, gaining access to 22,400 Nvidia GPUs. Tyson Foods raised its FY2026 revenue outlook as chicken sales offset beef weakness.
10 November 2025
····
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Pfizer will acquire obesity drug developer Metsera in a deal worth up to $10 billion, with a shareholder vote set for Nov. 13. Novo Nordisk shares rose after it exited the bidding. Norway’s $1.5 trillion sovereign wealth fund said it will abstain from voting on Novo’s new board at a meeting Nov. 14. Novo also signed a deal to distribute its semaglutide weight-loss shot in India under the brand Poviztra.
10 November 2025
··
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera agreed to Pfizer’s revised takeover offer worth up to $10 billion after Novo Nordisk withdrew from bidding. The deal values Metsera at $86.25 per share, including $65.60 in cash and up to $20.65 via a contingent value right. Metsera shareholders will vote on the merger November 13. Both companies expect a swift closing if approved.
8 November 2025
····
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Pfizer secured a deal to acquire obesity-drug developer Metsera for up to $10 billion after Novo Nordisk withdrew its rival bid, citing FTC antitrust concerns. Metsera shareholders are set to vote Nov. 13 on Pfizer’s offer of $65.60 in cash plus up to $20.65 per share in contingent value rights. Metsera’s board recommended approval. Metsera shares surged nearly 60% during the bidding.
8 November 2025
···
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer will acquire Metsera for up to $10 billion after Metsera accepted a revised cash-and-CVR offer late Friday, ending Novo Nordisk’s competing bid. Metsera’s board cited U.S. antitrust risks with Novo’s proposal following FTC feedback. Pfizer will pay $65.60 per share plus a contingent value right of up to $20.65. A shareholder vote is set for Nov. 13, with closing expected soon after.
8 November 2025
···
1 … 3 4 5 6 7

Stock Market Today

  • Marwyn Value Investors Limited Shares Major Stake Notification
    June 10, 2026, 6:28 AM EDT. On June 9, 2026, Marwyn Investment Management LLP notified a major interest in Marwyn Value Investors Limited, crossing the 18.92% voting rights threshold. The notification, filed on June 10, 2026, indicates 1,070,000 voting rights held via direct shares, representing a significant stake. The disclosure highlights the regulatory requirement for investors to report acquisitions of substantial voting rights, impacting control and shareholder influence. Marwyn Value Investors Limited is a non-UK issuer, with Pershing Securities Limited acting as the shareholder notifier. The transaction was completed in Jersey, underscoring transparency in shareholder positions for market participants and regulators.

Latest articles

US stock futures slip with CPI ahead as Iran oil risk stirs Fed worries

US stock futures slip with CPI ahead as Iran oil risk stirs Fed worries

10 June 2026
S&P 500, Nasdaq 100, and Dow futures fell sharply premarket as investors braced for the May CPI report, expected to show the fastest annual inflation since April 2023, with tech stocks hit hardest amid rising oil prices and fresh U.S.-Iran strikes, raising fears of persistent inflation and fewer Fed rate cuts.
Erie Insurance gains 15 spots to No. 308 on Fortune 500

Erie Insurance gains 15 spots to No. 308 on Fortune 500

10 June 2026
Erie Insurance jumped 15 spots to No. 308 on the 2026 Fortune 500 with $14.6 billion in revenue, easily clearing the $7.5 billion cutoff as the bar rose 5%, but analysts warn U.S. property-and-casualty insurers face softer pricing, more competition, and rising catastrophe risks, with 2026 premium growth forecast to slow and return on equity to ease after a strong 2025.
Oracle Stock Moves Higher as AI Backlog Draws Focus

Oracle Faces $600 Billion AI Bet as Traders Watch for Volatility

10 June 2026
Oracle shares slid nearly 3% to $205.81 ahead of Wednesday’s earnings, as investors await proof that its $553 billion AI cloud backlog can convert to revenue quickly enough to justify heavy data-center spending, with options pricing signaling an 11% stock swing after results.
DraftKings (DKNG) Moves After Prediction-Market News — Traders Focus on Stock

DraftKings (DKNG) Moves After Prediction-Market News — Traders Focus on Stock

10 June 2026
DraftKings shares soared 11.34% to $27.59 after revealing a 24% month-over-month jump in annualized consumer volume to $1.3 billion and a 34% rise in total volume traded to $3.1 billion in its Predictions product for May, based on preliminary, unaudited data, outpacing a falling Nasdaq and spotlighting investor focus on the product’s revenue potential and DraftKings’ strategic push.
Micron Stock’s $1 Trillion AI Test Is Here as Traders Look to June 24

Micron Stock’s $1 Trillion AI Test Is Here as Traders Look to June 24

10 June 2026
Micron shares fell 1.5% to $935.89 as the AI-chip rally cooled, despite bullish analyst calls and price targets up to $1,625; investors await the June 24 earnings report to see if tight memory chip supply and AI demand can sustain the stock’s trillion-dollar valuation amid broader market jitters and shifting sentiment.
Go toTop